FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 323:295-301 August 2, 1990 Number 5 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

BACKGROUND AND METHODS. Chronic hepatitis B is a common and often progressive liver disorder for which there is no accepted therapy. To assess the efficacy of treatment with interferon, we randomly assigned patients with chronic hepatitis B to one of the following regimens: prednisone for 6 weeks followed by 5 million units of recombinant interferon alfa-2b daily for 16 weeks; placebo followed by 5 million units of interferon daily for 16 weeks; placebo followed by 1 million units of interferon daily for 16 weeks; or observation with no treatment. RESULTS. Hepatitis B e antigen and hepatitis B viral DNA disappeared from serum significantly more often in the patients given prednisone plus interferon (16 of 44 patients, or 36 percent) or 5 million units of interferon alone (15 of 41; 37 percent) than in the untreated controls (3 of 43; 7 percent; P less than 0.001); the difference between those given 1 million units of interferon (7 of 41; 17 percent) and the controls was not significant. The strongest independent predictor of a response to treatment was the amount of hepatitis B viral DNA in serum at entry (P less than 0.0001). Of the 38 patients who responded to interferon, 33 (87 percent) had normal serum aminotransferase levels after therapy; 11 patients who responded (29 percent), but no controls, lost the hepatitis B surface antigen. Blinded histologic assessment revealed a significant improvement in periportal necrosis in the treated patients (P = 0.03). CONCLUSIONS. In chronic hepatitis B, treatment with interferon alfa-2b (5 million units per day for 16 weeks) was effective in inducing a sustained loss of viral replication and achieving remission, assessed biochemically and histologically, in over a third of patients. Moreover, in about 10 percent of the patients treated with interferon, hepatitis B surface antigen disappeared from serum.

Source Information

St. Louis Veterans Affairs Medical Center, MO 63106.

This article has been cited by other articles:

• Shamliyan, T. A., MacDonald, R., Shaukat, A., Taylor, B. C., Yuan, J.-M., Johnson, J. R., Tacklind, J., Rutks, I., Kane, R. L., Wilt, T. J. (2009). Antiviral Therapy for Adults With Chronic Hepatitis B: A Systematic Review for a National Institutes of Health Consensus Development Conference. ANN INTERN MED 150: 111-124 [Abstract] [Full Text]  
• Marcellin, P., Heathcote, E. J., Buti, M., Gane, E., de Man, R. A., Krastev, Z., Germanidis, G., Lee, S. S., Flisiak, R., Kaita, K., Manns, M., Kotzev, I., Tchernev, K., Buggisch, P., Weilert, F., Kurdas, O. O., Shiffman, M. L., Trinh, H., Washington, M. K., Sorbel, J., Anderson, J., Snow-Lampart, A., Mondou, E., Quinn, J., Rousseau, F. (2008). Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B. NEJM 359: 2442-2455 [Abstract] [Full Text]  
• Dienstag, J. L. (2008). Hepatitis B Virus Infection. NEJM 359: 1486-1500 [Full Text]  
• Lai, C.-L., Gane, E., Liaw, Y.-F., Hsu, C.-W., Thongsawat, S., Wang, Y., Chen, Y., Heathcote, E. J., Rasenack, J., Bzowej, N., Naoumov, N. V., Di Bisceglie, A. M., Zeuzem, S., Moon, Y. M., Goodman, Z., Chao, G., Constance, B. F., Brown, N. A., the Globe Study Group, (2007). Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B. NEJM 357: 2576-2588 [Abstract] [Full Text]  
• Valsamakis, A. (2007). Molecular Testing in the Diagnosis and Management of Chronic Hepatitis B. Clin. Microbiol. Rev. 20: 426-439 [Abstract] [Full Text]  
• Bonino, F, Marcellin, P, Lau, G K K, Hadziyannis, S, Jin, R, Piratvisuth, T, Germanidis, G, Yurdaydin, C, Diago, M, Gurel, S, Lai, M-Y, Brunetto, M R, Farci, P, Popescu, M, McCloud, P, for the Peginterferon Alfa-2a HBeAg-Negative Chron, (2007). Predicting response to peginterferon {alpha}-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 56: 699-705 [Abstract] [Full Text]  
• Kim, J. W, Park, S. H, Louie, S. G (2006). Telbivudine: A Novel Nucleoside Analog for Chronic Hepatitis B. The Annals of Pharmacotherapy 40: 472-478 [Abstract] [Full Text]  
• Daftary, M. N., Goolsby, T., Farhat, F. (2006). An Update in the Management of Hepatitis B/HIV Coinfection. Journal of Pharmacy Practice 19: 31-36 [Abstract]  
• Flink, H J, Sprengers, D, Hansen, B E, van Zonneveld, M, de Man, R A, Schalm, S W, Janssen, H L A, for the HBV 99-01 study group, (2005). Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy. Gut 54: 1604-1609 [Abstract] [Full Text]  
• Boston, N. S., Slish, J. C. (2005). Management of HIV Infection in Persons Co-infected With Hepatitis. Journal of Pharmacy Practice 18: 295-309 [Abstract]  
• Lau, G. K., Piratvisuth, T., Luo, K. X., Marcellin, P., Thongsawat, S., Cooksley, G., Gane, E., Fried, M. W., Chow, W. C., Paik, S. W., Chang, W. Y., Berg, T., Flisiak, R., McCloud, P., Pluck, N., the Peginterferon Alfa-2a HBeAg-Positive Chronic H, (2005). Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B. NEJM 352: 2682-2695 [Abstract] [Full Text]  
• Shyamala, V., Arcangel, P., Cottrell, J., Coit, D., Medina-Selby, A., McCoin, C., Madriaga, D., Chien, D., Phelps, B. (2004). Assessment of the Target-Capture PCR Hepatitis B Virus (HBV) DNA Quantitative Assay and Comparison with Commercial HBV DNA Quantitative Assays. J. Clin. Microbiol. 42: 5199-5204 [Abstract] [Full Text]  
• Karayiannis, P. (2003). Hepatitis B virus: old, new and future approaches to antiviral treatment. J Antimicrob Chemother 51: 761-785 [Abstract] [Full Text]  
• Mailliard, M. E., Gollan, J. L. (2003). Suppressing Hepatitis B without Resistance -- So Far, So Good. NEJM 348: 848-850 [Full Text]  
• Berger, A., Preiser, W. (2002). Viral genome quantification as a tool for improving patient management: the example of HIV, HBV, HCV and CMV. J Antimicrob Chemother 49: 713-721 [Abstract] [Full Text]  
• Jonas, M. M., Kelley, D. A., Mizerski, J., Badia, I. B., Areias, J. A., Schwarz, K. B., Little, N. R., Greensmith, M. J., Gardner, S. D., Bell, M. S., Sokal, E. M., the International Pediatric Lamivudine Investigato, (2002). Clinical Trial of Lamivudine in Children with Chronic Hepatitis B. NEJM 346: 1706-1713 [Abstract] [Full Text]  
• Di Bisceglie, A M (2002). Combination therapy for hepatitis B. Gut 50: 443-445 [Abstract] [Full Text]  
• Chan, H. L. Y., Leung, N. W. Y., Lau, T. C. M., Wong, M. L., Sung, J. J. Y. (2000). Comparison of Three Different Sensitive Assays for Hepatitis B Virus DNA in Monitoring of Responses to Antiviral Therapy. J. Clin. Microbiol. 38: 3205-3208 [Abstract] [Full Text]  
• Malik, A. H., Lee, W. M. (2000). Chronic Hepatitis B Virus Infection: Treatment Strategies for the Next Millennium. ANN INTERN MED 132: 723-731 [Abstract] [Full Text]  
• Chen, T., Luk, J. M., Cheung, S.-T., Yu, W.-C., Fan, S.-T. (2000). Evaluation of Quantitative PCR and Branched-Chain DNA Assay for Detection of Hepatitis B Virus DNA in Sera from Hepatocellular Carcinoma and Liver Transplant Patients. J. Clin. Microbiol. 38: 1977-1980 [Abstract] [Full Text]  
• Schalm, S W, Heathcote, J, Cianciara, J, Farrell, G, Sherman, M, Willems, B, Dhillon, A, Moorat, A, Barber, J, Gray, D F, International Lamivudine Study Group, (2000). Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 46: 562-568 [Abstract] [Full Text]  
• Kessler, H. H., Preininger, S., Stelzl, E., Daghofer, E., Santner, B. I., Marth, E., Lackner, H., Stauber, R. E. (2000). Identification of Different States of Hepatitis B Virus Infection with a Quantitative PCR Assay. CVI 7: 298-300 [Abstract] [Full Text]  
• Dienstag, J. L., Schiff, E. R., Wright, T. L., Perrillo, R. P., Hann, H.-W. L., Goodman, Z., Crowther, L., Condreay, L. D., Woessner, M., Rubin, M., Brown, N. A., The U.S. Lamivudine Investigator Group, (1999). Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States. NEJM 341: 1256-1263 [Abstract] [Full Text]  
• Zhou, T., Saputelli, J., Aldrich, C. E., Deslauriers, M., Condreay, L. D., Mason, W. S. (1999). Emergence of Drug-Resistant Populations of Woodchuck Hepatitis Virus in Woodchucks Treated with the Antiviral Nucleoside Lamivudine. Antimicrob. Agents Chemother. 43: 1947-1954 [Abstract] [Full Text]  
• Balfour, H. H. (1999). Antiviral Drugs. NEJM 340: 1255-1268 [Full Text]  
• Koudriavtseva, T, Pozzilli, C, Fiorelli, M, Gasperini, C, Bagnato, F, Galgani, S, Frontoni, M, Ciccarelli, O, Bastianello, S (1998). Determinants of Gd-enhanced MRI response to IFN-{beta}-1a treatment in relapsing-remitting multiple sclerosis. Mult Scler 4: 403-407 [Abstract]  
• Lai, C.-L., Chien, R.-N., Leung, N. W.Y., Chang, T.-T., Guan, R., Tai, D.-I., Ng, K.-Y., Wu, P.-C., Dent, J. C., Barber, J., Stephenson, S. L., Gray, D. F., The Asia Hepatitis Lamivudine Study Group, (1998). A One-Year Trial of Lamivudine for Chronic Hepatitis B. NEJM 339: 61-68 [Abstract] [Full Text]  
• Petersen, J., Dandri, M., Gupta, S., Rogler, C. E. (1998). Liver repopulation with xenogenic hepatocytes in B and T cell-deficient mice leads to chronic hepadnavirus infection and clonal growth of hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA 95: 310-315 [Abstract] [Full Text]  
• Lee, W. M. (1997). Hepatitis B Virus Infection. NEJM 337: 1733-1745 [Full Text]  
• Ballow, M., Nelson, R. (1997). Immunopharmacology: Immunomodulation and Immunotherapy. JAMA 278: 2008-2017 [Abstract]  
• Gitlin, N. (1997). Hepatitis B: diagnosis, prevention, and treatment. Clin. Chem. 43: 1500-1506 [Abstract] [Full Text]  
• Hoofnagle, J. H., Di Bisceglie, A. M. (1997). The Treatment of Chronic Viral Hepatitis. NEJM 336: 347-356 [Full Text]  
• Niederau, C., Heintges, T., Lange, S., Goldmann, G., Niederau, C. M., Mohr, L., Haussinger, D. (1996). Long-Term Follow-Up of HBeAg-Positive Patients Treated with Interferon Alfa for Chronic Hepatitis B. NEJM 334: 1422-1427 [Abstract] [Full Text]  
• Hoofnagle, J. H., Lau, D. (1996). Chronic Viral Hepatitis -- Benefits of Current Therapies. NEJM 334: 1470-1471 [Full Text]  
• Dienstag, J. L., Perrillo, R. P., Schiff, E. R., Bartholomew, M., Vicary, C., Rubin, M. (1995). A Preliminary Trial of Lamivudine for Chronic Hepatitis B Infection. NEJM 333: 1657-1661 [Abstract] [Full Text]  
• Merigan, T. C. (1995). A Quarter-Century of Antiviral Therapy. NEJM 333: 1704-1705 [Full Text]  
• McKenzie, R., Fried, M. W., Sallie, R., Conjeevaram, H., Di Bisceglie, A. M., Park, Y., Savarese, B., Kleiner, D., Tsokos, M., Luciano, C., Pruett, T., Stotka, J. L., Straus, S. E., Hoofnagle, J. H. (1995). Hepatic Failure and Lactic Acidosis Due to Fialuridine (FIAU), an Investigational Nucleoside Analogue for Chronic Hepatitis B. NEJM 333: 1099-1105 [Abstract] [Full Text]  
• Swartz, M. N. (1995). Mitochondrial Toxicity -- New Adverse Drug Effects. NEJM 333: 1146-1148 [Full Text]  
• Farci, P., Mandas, A., Coiana, A., Lai, M. E., Desmet, V., Van Eyken, P., Gibo, Y., Caruso, L., Scaccabarozzi, S., Criscuolo, D., Ryff, J.-C., Balestrieri, A. (1994). Treatment of Chronic Hepatitis D with Interferon Alfa-2a. NEJM 330: 88-94 [Abstract] [Full Text]  
• Di Bisceglie, A. M. (1994). Interferon Therapy for Chronic Viral Hepatitis. NEJM 330: 137-138 [Full Text]  
• Lehtovaara, P, Uusi-Oukari, M, Buchert, P, Laaksonen, M, Bengtstrom, M, Ranki, M (1993). Quantitative PCR for hepatitis B virus with colorimetric detection.. Genome Res 3: 169-175 [Abstract]  
• Hill, N. O. (1992). Hepatitis C after Needlestick Injuries. ANN INTERN MED 116: 345-346 [Abstract]  
• Baron, S., Tyring, S. K., Fleischmann, W. R. Jr, Coppenhaver, D. H., Niesel, D. W., Klimpel, G. R., Stanton, G. J., Hughes, T. K. (1991). The Interferons: Mechanisms of Action and Clinical Applications. JAMA 266: 1375-1383 [Abstract]  
• (1991). From the Centers for Disease Control. JAMA 266: 771-776  
• Perrillo, R. P., Brunt, E. M. (1991). Hepatic Histologic and Immunohistochemical Changes in Chronic Hepatitis B after Prolonged Clearance of Hepatitis B e Antigen and Hepatitis B Surface Antigen. ANN INTERN MED 115: 113-115 [Abstract]  
• Carey, W. D. (1991). Gastroenterology and Hepatology. JAMA 265: 3121-3123 [Abstract]  
• Korenman, J., Baker, B., Waggoner, J., Everhart, J. E., Di Bisceglie, A. M., Hoofnagle, J. H. (1991). Long-Term Remission of Chronic Hepatitis B after Alpha-Interferon Therapy. ANN INTERN MED 114: 629-634 [Abstract]  
• (1990). INTERFERON IS EFFECTIVE AGAINST CHRONIC HEPATITIS B. JWatch General 1990: 4-4 [Full Text]